Experts support UK age limit for AstraZeneca jab deployment

A clear contrast between the UK’s approach to the use of the Oxford / AstraZeneca vaccine and many other countries was revealed Thursday morning.

When British Health Minister Matt Hancock toured the broadcast studio and defended the decision to limit people under the age of 30 from having jabs, his counterparts in other countries Spain and italy Use in the Philippines was restricted to people over the age of 60.

“People can be confident in the fact that there are world-class regulators that are completely transparent to the data and are taking a cautious approach to making the deployment of this vaccine as safe as possible.” Hancock told the BBC Radio.

Observers say the UK’s “careful approach” is not only the risks and benefits of the AstraZeneca vaccine itself, but also the possibility of developing very rare blood disorders after jabs and the harm caused by serious cases of Covid-19. He said that he is considering the balance with. In addition, the vaccination program should be continued to provide jabs to all adults by the end of July.

The government expects that there will be sufficient supply to use either the BioNTech / Pfizer or Moderna vaccine in place of AstraZeneca for people under the age of 30. Groups aged 18-29 will receive jabs from the beginning of June, although the timeline may be slightly delayed.

However, if AstraZeneca’s jab is only allowed to people over the age of 55 or 60, the developments that have had a significant impact on reducing the death toll of Covid-19 in the United Kingdom are completely off course. .. Most of them have already been vaccinated in the UK. — As in many other countries, including Germany and France.

Michael Head, Senior Research Fellow, Global Health, University of Southampton, said: “The UK does not have a high level of vaccine repellent compared to other European countries and it is correct to continue deployment while safety signals are being investigated.”

According to a study by the Winton Center for Risk and Evidence Communication at the University of Cambridge, people in their thirties who are at moderate risk of being exposed to Covid-19 are more likely to receive intensive care for the disease than to suffer serious harm. It has been shown to be twice as expensive. From AstraZeneca vaccine. For people in their 60s, the risk of serious Covid-19 is 200 times the serious harm of jabs. The risks posed by Covid-19 and jabs vary depending on the infection rate.

Sir Kent Woods, former CEO of the UK Medicines and Healthcare Products Regulatory Agency, said Wednesday in a “carefully and clearly discussed” presentation by regulators led by him and a subsequent joint committee explanation. “I’m very confident,” he said. For vaccinations and vaccinations, why we encourage people under the age of 30 to receive an AstraZeneca alternative jab.

“I’ve never seen such an evidence-based analysis on the continent. It feels like they’re pulling a person out of the air,” he said. “The decision-making process in France, Germany and elsewhere was chaotic in many ways,” he added. “There was a disconnect between the activities of the European Medicines Agency and the member states of the country.”

MHRA and EMA are regulators who have worked closely together to reach similar conclusions about the side effects of the AstraZeneca vaccine. However, JCVI and other national response agencies are advisory bodies that take national circumstances into account in their recommendations to the government.

Simon Kroll, a professor of pediatrics and molecular infections at Imperial College London and a member of JCVI, said MHRA was able to investigate cases of dangerous blood clotting with a decrease in platelet count after AstraZeneca vaccination. He said it moved as quickly as possible. By March 31, 79 cases had been reported in the United Kingdom, including 19 deaths.

“The solutions to these medical challenges can be imagined to occur in the same way as on television,” Kroll said. “But it takes time to collect data, understand case records across the country, and put them all together.”

He said decisions by authorities in other countries may reflect different perceptions of risk there. “We have an NHS that is highly trusted and is seen to act for the benefit of the people. Behind the vaccination is the NHS, which gives us the advice given in good faith. Gave me the entire population to accept, “said Kroll.

“if [other countries] Since we are working on the same data presented in the UK, we must assume that those conclusions were dictated by considerations other than just the risk figures. ”

Johannes Oldenberg, a professor of transfusion medicine at the University of Bonn, said that the permanent immunization committee, which corresponds to the German JCVI, is relatively “very conservative” and tends to act with due diligence. Said.

German regulators advise that people under the age of 60 who receive the first injection of the AstraZeneca vaccine should not receive a second dose, even if there are no side effects.

Oldenburg said this “may be okay” in Germany, which does not rely heavily on the AstraZeneca vaccine for its vaccination program, but “other countries cannot be so conservative.”

In the United States, Lawrence Gostyn, a professor of public health law at Georgetown University, has called on regulators to take global views and risks that further undermine public confidence in vaccines. AstraZeneca jabs are considered the key to immunization programs in poor countries because they are cheaper and easier to store and handle than many other countries.

“We have a dizzying array of different judgments from different regulators. It can be very destructive for each country to take its own path,” Gostyn said. This can be particularly detrimental to low-income countries seeking a seal of approval from Western regulators. “This is not just a European turmoil, but a global turmoil.”

Experts support UK age limit for AstraZeneca jab deployment

Source link Experts support UK age limit for AstraZeneca jab deployment

Exit mobile version